Biome Australia (ASX:BIO) Expands Its Probiotics and Manufacturing Strategy

Aditi Sarkar

10 September 2026 10:40 PM AEST

Biome Australia (ASX:BIO) Expands Its Probiotics and Manufacturing Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Biome Australia (ASX:BIO) is expanding its probiotics Business after reporting record FY2026 sales. The consumer-health company is pairing higher pharmacy sell-through with an onshore Manufacturing agreement intended to improve Supply control and support international growth.

Latest Developments

Biome Australia reported record FY2026 sales Revenue of A$23.9 million, describing Biome Daily as the leading probiotic product by units sold in Australian community pharmacies. The June half delivered revenue of about A$11.5 million, up 20% on the prior year, and June marked the first month with sell-through exceeding 100,000 units, a milestone that points to accelerating consumer Demand at the pharmacy counter.

Looking ahead, the company pointed to a June 2026 agreement with Specialty Probiotics Australia for onshore manufacturing, with the first commercial batch targeted for September 2026, a step it expects to support materially stronger international growth. Localising production is intended to give Biome greater control over supply, quality and lead times as it scales, while reducing exposure to offshore manufacturing bottlenecks.

What Could Come Next

Key signposts include the first commercial batch from the onshore manufacturing arrangement, targeted for September 2026, continued growth in pharmacy sell-through, and progress on international expansion. Investors will also look for updates on profitability as the business scales and any new product launches within the Activated Probiotics range. Further gains in international revenue, which remains a small share of the total, would help demonstrate that the Brand can travel beyond its established Australian pharmacy base.

Risks to Watch

Consumer-health growth companies face competition, execution and Margin risks. The probiotics category is competitive, and maintaining category Leadership requires ongoing Marketing and product investment. Investors should also note that profitability details were limited in the reported figures, so the path to sustained Earnings remains a key watch-point.

Conclusion

Biome has paired record sales with a plan to localise manufacturing and expand internationally. The next stage depends on successful production transfer, continued pharmacy demand, competitive positioning and progress towards sustained profitability.

FAQs

Q: What defines the current strategy of Biome Australia Ltd (ASX:BIO)?

A: Biome Australia (ASX:BIO) is expanding its probiotics business after reporting record FY2026 sales. The consumer-health company is pairing higher pharmacy sell-through with an onshore manufacturing agreement intended to improve supply control and support international growth.

Q: What could come next for Biome Australia Ltd (ASX:BIO)?

A: Key signposts include the first commercial batch from the onshore manufacturing arrangement, targeted for September 2026, continued growth in pharmacy sell-through, and progress on international expansion. Investors will also look for updates on profitability as the business scales and any new product launches within the Activated Probiotics range.

Q: What are the key risks for Biome Australia Ltd (ASX:BIO)?

A: Consumer-health growth companies face competition, execution and margin risks. The probiotics category is competitive, and maintaining category leadership requires ongoing marketing and product investment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.